Most composite manufacturing problems are not discovered at the RFQ stage. They surface at first article inspection, when tooling is already committed. Or during validation, when documentation gaps appear that no one flagged at intake. Or at production ramp, when a process that worked on three prototype units fails to hold tolerances at volume. By the time the problem is visible, it is expensive. The evaluation that should have happened at sourcing did not ask the right questions.
This is not a failure of due diligence in general. It is a failure of specific questions — ones that are easy to skip when a supplier presents credentialing that looks right on paper. FDA registration and ISO 13485 certification matter, but they are baseline qualifications, not differentiators. The questions that reveal whether a composite manufacturer can actually execute your program are about how they work, not what they have on the wall.
Start With the Engineering Model, Not the Capability List
A composite manufacturer’s capability list tells you what processes they run. It does not tell you whether the engineering team that designs tooling is the same team that governs the production process — or whether those functions are separated in ways that create dimensional translation risk. Ask who owns both the tooling design and the fabrication process. When different teams manage those functions, or when tooling is outsourced, interpretations of drawing intent can differ, and corrections require coordination that adds time and cost at every stage of the program.
CMI’s in-house design and engineering model keeps both functions under one team. The engineers who design the molds work alongside the fabricators throughout pre-production and production. That continuity is not incidental — it is the structural feature of the manufacturing model that may reduce dimensional error and speed root cause resolution when something needs to be corrected.
Ask About Pre-Production, Not Just Prototyping
Many manufacturers offer prototyping. Fewer run a true pre-production stage — one that uses production tooling, a formally documented process, and inspection against drawing acceptance criteria. The distinction matters because a prototype confirms the design. A pre-production sample can provide evidence about the proposed production process. If your supplier cannot show that their pre-production samples are built on production tooling with a documented process, what they are giving you isn’t evidence of production capability. It is a best-effort part built under conditions that may not resemble production at all.
The questions to ask: Does the pre-production sample use production tooling or bridge tooling? Is the layup sequence, material specification, and cure cycle documented before fabrication begins? Is the sample inspected against drawing acceptance criteria, or against an internal standard that may not match your requirements? For regulated medical programs, can the documentation support design history file assembly? CMI’s pre-production sample fabrication process is built to answer all four questions affirmatively. That is what a pre-production stage is supposed to do.
Documentation Is a Program Risk, Not a Paperwork Requirement
Engineers sometimes treat documentation as an administrative burden that follows the real work of fabrication. Procurement teams sometimes treat it as a compliance checkbox. In regulated industries — medical devices, defense, aerospace — documentation is a program risk factor. A traceability gap discovered during a customer audit is a corrective action. A documentation gap discovered during FDA review is a delay. A process record that does not exist when a production problem needs to be root-caused is a guess.
Ask your supplier what documentation is standard for every program, not just for regulated clients. Material certifications, cure cycle records, and dimensional inspection records should not be add-ons that require negotiation. They should be the baseline. For medical device programs, ask specifically whether the supplier’s documentation practices are designed to support design history file requirements from the start of the program, not assembled after the fact. Suppliers who treat documentation as standard are also the ones who have fewer problems at first article and production approval — because the documentation discipline reflects the same process discipline that produces conforming parts. See how CMI’s manufacturing and assembly quality system maintains traceability from raw material through finished part.
Understand What the Quality Certifications Actually Cover
FDA registration and ISO 13485 certification may be important considerations in medical device composite manufacturing programs, depending on the supplier’s role and applicable requirements. However, these credentials alone may not provide a complete picture of a supplier’s capabilities or suitability for a specific program. The questions that matter are what the quality system actually covers and how long the supplier has operated under it.
- Does the ISO 13485 certification cover design controls, or only manufacturing? A supplier whose certification covers only manufacturing cannot support design history file documentation from intake.
- How long has the supplier operated under FDA registration? A supplier who registered recently to pursue medical device work has a different depth of regulated manufacturing experience than one who has operated under FDA registration for decades.
- Does the quality system align with the FDA’s current Quality Management System Regulation (QMSR), effective February 2, 2026? Suppliers still operating under the previous QSR framework may need to update their systems to meet current requirements.
CMI has been FDA-registered since 1985 and operates under an ISO 13485-compliant quality system that aligns with the current QMSR. That length of operation under a regulated quality system represents a different level of institutional depth than a recent certification.
Co-Molding and Integrated Assemblies: Ask Who Handles the Full Scope
Many composite parts for medical, defense, and aerospace programs do not ship as standalone carbon fiber components. They include metal interfaces, inserts, fasteners, or co-molded structural members that must integrate with the composite under tight dimensional and load-transfer requirements. If your composite manufacturer fabricates the carbon fiber component and hands it off to another supplier for metal integration, you introduce dimensional translation risk at the interface and split accountability for the final assembly’s performance.
Ask whether the supplier can handle the full assembly scope in-house, including co-molding carbon fiber with metal interfaces. For robotic arm and end effector programs, surgical table components, and defense structural assemblies, in-house co-molding capability means the engineering team manages dimensional requirements across both the composite and metal elements, with a single point of accountability for the finished assembly. This matters most when tolerances are tight, and the interface geometry is critical to the assembly’s function.
Application-Specific Experience Is Not the Same as General Composite Experience
A manufacturer who has produced aerospace composite structures for twenty years has real process expertise. That expertise does not automatically transfer to a medical device imaging component where radiolucency design, biocompatibility evaluation, and FDA documentation requirements are primary constraints. Ask whether the supplier has specific experience in your application category, not just in composite fabrication generally.
For radiolucency-critical applications — medical device components, radiation therapy equipment, imaging-guided surgical platforms — ask how many programs the supplier has executed where radiolucency was a primary design requirement and what design controls they applied. For surgical robotics programs, ask about specific experience with distal arm structures and end effector frames where inertial mass and stiffness-to-weight ratio are the governing design inputs. For radiation and nuclear applications, ask how the supplier evaluates resin system selection for cumulative dose environments rather than treating carbon fiber as generically suitable. General composite experience and application-specific experience are different things, and the distinction shows up in the quality of the engineering decisions made during program development.
The Evaluation That Happens Before the RFQ
The most productive supplier evaluations happen before the request for quote, not during it. When an engineer or procurement team engages a composite manufacturer during the design phase — before materials are locked in, before tooling is designed, before validation planning is underway — the manufacturer’s engineering input can shape design decisions that affect what is producible, what is documentable, and what the production cost will be. That input has the most value before the decisions are made, not after.
Late engagement typically means adapting a design to manufacturing constraints rather than optimizing for them. The cost of those adaptations shows up in engineering changes, extended lead times, and validation scope that exceeds what was planned. The questions outlined here — about engineering model, pre-production process, documentation standards, quality system depth, co-molding scope, and application-specific experience — are more useful before the RFQ than during it, because early in the program there is still time to act on the answers. Engaging CMI’s engineering team through the contact page early in your program development gives you access to that input when it can still change outcomes. Review CMI’s full composite solutions to understand the scope of what that conversation can cover.
The best time to evaluate a composite manufacturer is before the RFQ.
Contact CMI’s engineering team to discuss your program requirements before design decisions are locked in.
